Overview

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Status:
Completed

Trial end date:
2004-01-01

Target enrollment:

Participant gender:

Summary

Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.

Phase:

Phase 2

Details

Lead Sponsor:

Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.

Treatments:

Penicillins
Telavancin
Vancomycin